Yatarak tedavi gören şizofrenik hastalarda olanzapinle risperidonun karşılaştırılması
Bu çalışmada yatan şizofrenik hastalarda olanzapin ve risperidonun kısa süreli kullanımlarında etkinlik ve yan etki açısından karşılaştırılması amaçlandı. Yöntem: Çalışma psikiyatri kliniğine yatırılarak tedavi altına alınan ve en az 2 ay öncesinde psikotrop ilaç tedavisi almamış şizofrenili hastalarda gerçekleştirildi. Hastalara seçkisiz olarak olanzapin ve risperidon verildi. Hastaların tedaviye başlamadan önce ve her hafta için BPRS (Kısa psikiyatrik Değerlendirme Ölçeği) skorları belirlendi. Hastalar tarafından bildirilen yada çalışmacılar tarafından gözlenen ve sorgulanan yan etkiler kaydedildi. Ekstrapiramidal sendrom belirtileri Simpson-Angus Ölçeği (SAS) kullanarak değerlendirildi. Bulgular: İlk üç haftadaki antipsikotik etkinlik açısından iki ilaç arasında anlamlı bir farklılık ortaya çıkmadı. Yan etkiler açısından da önemli bir farklılık olmamasına rağmen risperidonla ekstrapiramidal, olanzapinle iştah ve kilo artışı gibi belirtilerin daha sık olduğu gözlendi. Sonuç: Bu iki ilacın antipsikotik etkinlik ve yan etkiler açısından benzerlik gösterdiği kanaatine varıldı.
A comparative study of olanzapine and risperidone in the treatment of schzophrenic inpatients
The aim of this study was to compare olanzapine and risperidone in terms of short-term antipsychotic efficiency and side effects in schizophrenic inpatients. Method: These two drugs were randomly given to the patients who had not taken any psychotropic drugs, at least for the last two months. Brief Psychiatric Rating Scale (BPRS) scores of the patients were determined before the treatment. Along with the treatment, this process was repeated once a week. All side effects, which had been reported by the patients themselves, or observed and questioned by us, were recorded. Extrapyramidal syndrome were determined by using Simpson-Angus Scale (SAS). Results: In the first three weeks, no significant difference of antipsychotic efficiency and side effects was observed between the two drugs. However, extrapyramidal side effects were observed to be more common in the patients taking risperidone, and increased appetite and weight gain in those taking olanzapine. Conclusion: The antipsychotic efficiency and side effects of risperidone and olanzapine were almost similar.
___
- 1. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376
- 2. Kahn RS. Atypical antipsychotic drugs. Ned Tijdschr Geneeskd 2000;144:1627- 1630
- 3. Gülseren L, Erol A. Şizofrenide ilaç sağaltımı. Klinik Psikofarmakoloji Bülteni 2000; 10: 213-227
- 4. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001; 52: 503-517
- 5. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61: 111-161
- 6. Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S,Hocherman S, Davidson M. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr Res 2000; 46: 81-89
- 7. Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry 2000; 61: 649-655
- 8. Yüksel N. Antipsikotik İlaçlar. Psikofarmakoloji. Ankara: Bilimsel Tıp Yayınevi, 1998: s: 58-121
- 9. Bhana N, Spencer CM. Risperidone: a review of its use in the manegement of the behavioural and psychological symptoms of dementia. Drugs Aging 2000; 16: 451-471
- 10. Stephenson CM, Pilowski LS. Psychopharmacology of olanzapine. A review. Br J Psychiatry 1999; 38: 52-58
- 11. Rabinowitz J, Lichtenberg P, Kaplan Z. Comparison of cost,dosage and clinical preference for risperidone and olanzapine. Schizophr Res 2000; 46: 91-96
- 12. Stahl SM. Antipsychotics agents. In: Stahl SM, (ed). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed., Cambridge: Cambridge University Press, 2000: 401-458
- 13. David SR, Taylor CC, Kinom BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22: 1085-1096
- 14. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdağ J, Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363
- 15. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-418
- 16. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60: 658-663
- 17. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC, American Psychiatric Association, 1994
- 18. Overal J, Gorham DR. The brief psychiatric rating scale. Psychological Reports, 1962; 10: 799-812
- 19. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatry Scandinavica, (Suppl) 1970; 212: 11-19
- 20. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane review).Cochrane Database Syst Rev 2000; CD 002306
- 21. Green B. Focus on risperidone. Curr Med Res Opin 2000; 16: 57-65